FDA approves Stanford Medicine-developed drug that treats rare …
3 days ago · The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed with a rare cardiovascular disease, transthyretin amyloid cardiomyopathy, or ATTR-CM.. The drug, acoramidis (Attruby), was originally developed by Isabella Graef, MD, former faculty member at the Stanford School of Medicine who is now the CEO of Shenandoah Therapeutics ...
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
5 days ago · The ATTRibute-CM Phase III trial, which formed the basis for the FDA’s approval, enrolled 632 subjects with symptomatic ATTR-CM. Credit: Theerani lerdsri/Shutterstock. The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR ...
FDA Approves Attruby - Drugs.com
About Attruby™ (acoramidis) Attruby is the only near-complete (≥90%) stabilizer of Transthyretin (TTR) approved in the U.S. for the treatment of adult patients with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. …
FDA approves drug for heart disorder caused by transthyretin …
6 days ago · The U.S. Food and Drug Administration has approved Attruby (acoramidis) to treat adults with cardiomyopathy (disorder that affects heart muscle) of wild-type or variant (hereditary)...
Bridgebio's Attruby, to Treat Heart Condition ATTR-CM, Receives …
5 days ago · The ATTRibute-CM Phase III study enrolled 632 participants with symptomatic ATTR-CM, associated with either wild-type or variant TTR. Participants were randomized 2:1 to receive Attruby or placebo ...
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), …
Industry News In The News. PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new type of biopharmaceutical company focused on genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) approved Attruby™ (acoramidis), an orally-administered near ...
BridgeBio announces FDA approved Attruby for ATTR-CM patients
Nov 23, 2024 · BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching
Nov 19, 2024 · BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a significant boost in the market against Pfizer’s tafamidis and potentially Alnylam’s Amvuttra.
BridgeBio heart disease drug Attruby wins FDA approval | STAT
Nov 23, 2024 · The FDA cleared Attruby to treat patients with the heart condition known as transthyretin amyloid cardiomyopathy, or ATTR-CM. Once thought to be a rare disease, ATTR-CM is now estimated to affect ...
FDA Approves New Drug for Life-Threatening Heart Condition
5 days ago · The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults with transthyretin amyloid cardiomyopathy, or ATTR-CM. ATTR-CM is a rare ...